Free Trial

Equity markets see knee-jerk drop lower,...>

EQUITIES
EQUITIES: Equity markets see knee-jerk drop lower, with the E-mini S&P briefly
entering negative territory on an FT story detailing that Gilead Science's
Remdesivir antiviral drug had 'flopped' in its first trial. The story goes on to
say that the Chinese trial showed that the drug did not improve patients'
condition or reduce the Coronavirus pathogen's presence in the bloodstream.
- E-mini S&P back in positive territory, but well below the earlier highs of
2836.75.
MNI London Bureau | +44 203-865-3809 | edward.hardy@marketnews.com
MNI London Bureau | +44 203-865-3809 | edward.hardy@marketnews.com

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.